Printer Friendly

Eisai receives approval for ACIPHEX Sprinkle.

M2 PHARMA-March 29, 2013-Eisai receives approval for ACIPHEX Sprinkle(C)2013 M2 COMMUNICATIONS

Eisai (TYO: 4523), a Japan-based pharmaceutical company, has received approval from the US FDA for ACIPHEX Sprinkle as a 12-week gastroesophageal reflux disease therapy for use in children between one to eleven years of age.

It was reported yesterday that the company has received the approval based on positive data from a multi-centre, double-blind trial conducted in 127 paediatric patients between one to 11 years of age with gastroesophageal reflux disease.

The parallel-group study included a treatment period of 12 weeks and an extension period of two dose levels of rabeprazole for 24 weeks.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 29, 2013
Words:118
Previous Article:Vetter Pharma's new centre for visual inspection and logistics passes first GMP inspection.
Next Article:Dr Reddya[euro](tm)s Shares Gain on US Announcement.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters